CHOLESTEROL MANAGEMENT IN THE UNITED STATES

Author(s)

Brook RA¹, Sax MJ², McManama SH², Smeeding JE³
¹The JeSTARx Group & NPRT, Newfoundland, NJ, USA, ²The Pharmacy Group, Glastonbury, CT, USA, ³The TPG-NPRT & JeSTARx, Glastonbury, CT, USA

Presentation Documents

PCV141-brook-ra-sup-1-sup-sax-mj-sup-2-sup-mcmanama-sh-sup-2-sup-strong-u-smeeding-je-u-sup-3-sup-strong-br-sup-1-sup-the-jestarx-group-nprt-newfoundland-nj-usa-sup-2-sup-the-pharmacy-group-glastonbury-ct-usa-sup-3-sup-the-tpg-nprt-jestarx- ...

OBJECTIVES: Many of the agents to treat hypercholesterolemia have become generically available. In recent years, newer targetted therapies have become available with different targets, higher prices and requiring clinician-administration. To understand how US managed care (MC) plans were using the various tools available to manage their formularies and members with hypercholesterolemia, hyperlipidemia and high trigylcerides

Conference/Value in Health Info

2016-10, ISPOR Europe 2016, Vienna, Austria

Value in Health, Vol. 19, No. 7 (November 2016)

Code

PCV141

Topic

Health Service Delivery & Process of Care

Topic Subcategory

Formulary Development

Disease

Cardiovascular Disorders

Explore Related HEOR by Topic

Healthcare Delivery

Presentation